Katherine Lewin is a news reporter who focuses on diabetes and obesity treatments, including the burgeoning GLP-1 market. She’s written extensively about everything from semaglutide to beta cell regeneration since joining the Endpoints team in 2022. Katherine previously worked as an enterprise reporter for The Florida Times-Union and USA Today and has been a part of fellowships with the Pulitzer Center for Crisis Reporting, Report for America and the Poynter-Koch Fellowship. She graduated with a degree in journalism and political science from Flagler College and is based in Florida.
Sign up for free to read a limited number of articles each month.About You
Pick what newsletters get delivered to your inbox each week.
Want unlimited access? Sign up for a premium subscription plan.